Showing 5281-5290 of 20465 results for "".
- Navigating Anesthesia Through CMS 2026 Fee Schedule Updateshttps://reachmd.com/news/navigating-anesthesia-through-cms-2026-fee-schedule-updates/2484510/CMS's 2026 Physician Fee Schedule finalizes structural and telehealth updates that will immediately affect anesthesia reven
- FDA Accepts sNDA for ZORYVE Cream 0.3% in Children Aged 2 to 5https://reachmd.com/news/fda-accepts-snda-for-zoryve-cream-03-in-children-ages-25/2484497/The US Food and Drug Administration (FDA) has accepted Arcutis Biotherapeutics’ supplemental New Drug Application (sNDA) seeking an expanded indication for ZORYVE® (roflumilast) cream 0.3% to include children ages 2 to 5 with plaque psoriasis.
- Predictive Power: Machine Learning in Colorectal Surgical Planninghttps://reachmd.com/news/predictive-power-machine-learning-in-colorectal-surgical-planning/2484490/A newly validated extreme gradient boosting (XGB) model improves preoperative prediction of omental metastasis in right-sided colon cancer and has immediate implications for surgical planning for patients at elevated risk. Investigators compared six machine-learning
- Pluri Launches Regenerative Aesthetics Subsidiary Cellav in Collaboration with Miss Universe Skincarehttps://reachmd.com/news/pluri-launches-regenerative-aesthetics-subsidiary-cellav-in-collaboration-with-miss-universe-skincare/2484496/Pluri Inc. has launched Cellav Health and Aesthetics Ltd., focused on science-based regenerative skincare. The company announced a strategic collaboration with Miss Universe Skincare to co-develop a new line of cell-based skincare products.
- Tralokinumab Maintains Efficacy in Hand AD Through 32 Weekshttps://reachmd.com/news/tralokinumab-maintains-efficacy-in-hand-ad-through-32-weeks/2484484/LEO Pharma has announced positive 32-week topline results from its ADHAND trial, a phase 3b study evaluating tralokinumab in adults with moderate-to-severe atopic dermatitis (AD) with hand involvement. According to a press rele
- Exploring Biomarkers for Metabolic Complications in NAFLD: The Uric Acid-to-Creatinine Ratiohttps://reachmd.com/news/exploring-biomarkers-for-metabolic-complications-in-nafld-the-uric-acid-to-creatinine-ratio/2484471/According to a recent study, uric acid-to-creatinine ratio (SUA/Cr) identifies metabolic risk and may support screening and risk stratification in patients with non-alcoholic
- Ultra-processed Food Consumption and Early-Onset Colorectal Cancer Riskhttps://reachmd.com/news/ultra-processed-food-consumption-and-early-onset-colorectal-cancer-risk/2484478/Mass General Brigham reports that high intake of ultra-processed foods is linked to a substantially higher risk of conventional colorectal adenomas in adults under
- Exploring Slowly Expanding Lesions in Pediatric-Onset Multiple Sclerosishttps://reachmd.com/news/exploring-slowly-expanding-lesions-in-pediatric-onset-multiple-sclerosis/2484449/Detection of slowly expanding lesions (SELs) in pediatric-onset MS identifies a reproducible imaging correlate linked to accelerated tissue loss and worse structural ou
- SEZ6: An Emerging Role in Neuroendocrine Carcinomashttps://reachmd.com/news/sez6-an-emerging-role-in-neuroendocrine-carcinomas/2484460/SEZ6 is a neuronal membrane protein now implicated in high-grade neuroendocrine carcinomas. These tumors are clinically aggressive and lack durable systemic therapies, heightening the
- Unveiling FGD3: A New Ally in the Fight Against Breast Cancerhttps://reachmd.com/news/unveiling-fgd3-a-new-ally-in-the-fight-against-breast-cancer/2484466/FGD3 sensitizes breast tumors to chemotherapy and immunotherapy in preclinical models by triggering cancer-cell swelling and membrane rupture